R.M. Rozendaal, E.J. Uitterlinden, G.J.V.M. van Osch, E.H. Garling, S.P. Willemsen, A.Z. Ginai, J.A.N. Verhaar, H. Weinans, B.W. Koes and S.M.A. Bierma-Zeinstra
Recently it was reported that glucosamine sulphate (GS) did not have an effect on the symptoms and progression of primary care patients with hip osteoarthritis (OA). The aim of this present study was to investigate whether there are subgroups of patients with hip OA for whom GS might be an effective therapy. 222 patients with hip OA either had 1500 mg of oral GS or placebo once daily for 2 years. Subgroup analyses were predefined for radiographic severity and for type of OA (localised vs generalised). Additional exploratory subgroup analyses focused on groups based on pain level, pain medication use, baseline joint space width (JSW), and concomitant knee OA at baseline.
In the predefined subgroups based on radiographic severity and type of OA, the outcomes WOMAC pain, function and JSN were similar for the GS and placebo group. It was therefore concluded that GS was not significantly better than placebo in reducing symptoms and progression of hip OA in subgroups of patients.
Osteoarthritis and Cartilage, Volume 17, Issue 4, April 2009, Pages 427-432